Ajax Therapeutics

Others

Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms

Fineline Cube Apr 28, 2026

Eli Lilly and Company (NYSE: LLY) and Ajax Therapeutics, Inc. announced a definitive agreement on...

Company Deals

Junshi Biosciences Secures Global Exclusive Rights to CAS’s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal

Company Drug

Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC

Company Drug

Createrna’s MY008211A Becomes China’s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria

Policy / Regulatory

China’s CDE Releases 107th Batch of Reference Preparations for Generic Drug Consistency Evaluation with 17 New Drugs Added